Table 1.
Predicted CTL epitopes for SARS-CoV nucleocapsid protein.
Name | Position | Sequence | SYFPEITHIa | BIMASb | BL50 (μM)c |
---|---|---|---|---|---|
N-113 | 113–122 | YLGTGPEASL | 98.3 | 26 | 25.7 ± 11.2 |
N-159 | 159–168 | VLQLPQGTTL | 309.1 | 29 | 235.3 ± 68.7 |
N-222 | 222–231 | LLLLDRLNQL | 69.6 | 24 | 52.6 ± 10.5 |
N-223 | 223–231 | LLLDRLNQL | 98.3 | 20 | 46.1 ± 4.9 |
N-227 | 227–235 | RLNQLESKV | 36.3 | 23 | 165.1 ± 36.6 |
N-317 | 317–325 | GMSRIGMEV | 1267.1 | 30 | 72.8 ± 37.7 |
N-331 | 331–340 | WLTYHGAIKL | 50.2 | 21 | 90.4 ± 39.2 |
N-352 | 352–360 | ILLNKHIDA | 31.2 | 19 | 140.5 ± 44.6 |
Peptide binding scores to HLA-A2.1 were determined by the SYFPEITHI database [16] at http://www.syfpeithi.de/.
Peptide binding scores to HLA-A2.1 were determined by the BIMAS database [17] at http://www-bimas.cit.nih.gov/molbio/hla_bind/.
Data of peptide binding assays are shown as BL50, indicating a concentration of each peptide that yields the half-maximal MFI of T2 cells pulsed with a control peptide, NS3-1585. Data are given as mean values ± SD of three independent experiments.